Acadia Pharmaceuticals (ACAD) Total Current Liabilities (2010 - 2026)

Acadia Pharmaceuticals' Total Current Liabilities history runs 17 years deep, the most recent figure standing at $305.5 million for Q1 2026.

• On a quarterly basis, Total Current Liabilities rose 0.99% year-over-year to $305.5 million in Q1 2026; TTM through Mar 2026 was $305.5 million, a 0.99% increase from a year earlier, with the FY2025 full-year figure at $277.1 million, down 29.82% from the prior year.
• Total Current Liabilities advanced to $305.5 million in Q1 2026 per ACAD's latest filing, from $277.1 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $394.9 million in Q4 2024 and bottomed at $116.6 million in Q3 2022.
• The 5-year median for Total Current Liabilities is $277.1 million (2025), against an average of $255.0 million.
• Across the five-year window, Total Current Liabilities jumped 102.38% in 2023 and retreated 29.82% in 2025, its largest moves.
• Year by year, Total Current Liabilities stood at $125.6 million in 2022, then soared by 102.38% to $254.3 million in 2023, then surged by 55.31% to $394.9 million in 2024, then slipped by 29.82% to $277.1 million in 2025, then gained by 10.25% to $305.5 million in 2026.
• Per Business Quant, the three latest ACAD Total Current Liabilities figures stand at $305.5 million (Q1 2026), $277.1 million (Q4 2025), and $356.6 million (Q3 2025).